ClinConnect ClinConnect Logo
Search / Trial NCT06542016

An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients

Launched by SHENZHEN SECOND PEOPLE'S HOSPITAL · Aug 2, 2024

Trial Information

Current as of April 28, 2025

Recruiting

Keywords

Chronic Kidney Disease Stage 5 Maintenance Dialysis Heart Failure Cardiovascular Outcomes Kansas City Cardiomyopathy Questionnaire Patient Self Reported Outcomes

ClinConnect Summary

This clinical trial is studying how well the Kansas City Cardiomyopathy Questionnaire (KCCQ) can help predict the risk of heart problems in patients with severe kidney disease who are on dialysis. Heart disease is a major concern for these patients, and the KCCQ is a tool designed to measure their heart health and quality of life. By looking at KCCQ scores over time, researchers hope to understand if these scores can help identify patients at higher risk of heart issues or death, allowing for better care and treatment.

To participate in this study, individuals need to be at least 18 years old and have chronic kidney disease stage 5, whether they are just starting dialysis or have been receiving it for some time. Patients should also be able to complete the KCCQ questionnaire and have contact information available for follow-up. Those with certain serious heart conditions, recent heart surgeries, or other significant health issues will not be eligible. Participants can expect to complete the KCCQ at the beginning and during the study, and their responses will help improve understanding and treatment of heart health in dialysis patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 18 or older with no restrictions on gender or ethnicity;
  • 2. All enrolled patients meet the diagnostic criteria for CKD stage 5 according to the KDOQI guidelines of the National Kidney Foundation;
  • 3. Newly diagnosed uremia patients planning to start maintenance dialysis (hemodialysis or peritoneal dialysis), as well as patients currently undergoing maintenance dialysis treatment (hemodialysis or peritoneal dialysis);
  • 4. Clear contact information is available to reach patients or family members for follow-up;
  • 5. Signed informed consent and ability to complete the KCCQ.
  • Exclusion Criteria:
  • 1. Patients with acute kidney injury from various causes;
  • 2. Patients with severe mental illnesses that affect their ability to complete questionnaires;
  • 3. Patients who have had acute myocardial infarction, coronary artery stent implantation, coronary artery bypass grafting (CABG) or pacemaker implantation within the past three months;
  • 4. Patients with special types of heart disease, including cardiac amyloidosis, congenital heart disease and pericardial diseases;
  • 5. Patients with chronic lung diseases;
  • 6. Patients with serious underlying conditions such as severe infections, tumors or severe liver diseases;
  • 7. Patients scheduled for kidney transplantation.

About Shenzhen Second People's Hospital

Shenzhen Second People's Hospital is a leading healthcare institution located in Shenzhen, China, known for its commitment to advancing medical research and clinical innovation. As a prominent clinical trial sponsor, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experienced professionals to conduct high-quality research aimed at improving patient outcomes. The institution is dedicated to adhering to rigorous ethical standards and regulatory compliance while fostering collaborations with academic and industry partners to explore novel therapeutic interventions across various medical fields. Through its clinical trials, Shenzhen Second People's Hospital aims to contribute significantly to the global body of medical knowledge and enhance evidence-based practices in healthcare.

Locations

Guangdong, Guangdong, China

Patients applied

0 patients applied

Trial Officials

QiJun Wan

Study Director

Shenzhen Second People's Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported